Brief Culturally Adapted Cognitive Behavior Therapy for Psychosis

October 27, 2014 updated by: Fraooq Naeem, Pakistan Association of Cognitive Therapists

A Randomized Controlled Trial of Brief Culturally Adapted CBT for Schizophrenia in Pakistan

While Cognitive behavior therapy for psychosis (CBTp) is now established as an effective and evidence based therapy for psychotic illnesses in the west and is recommended by the national organizations both in Europe and in the USA. However, CBT remains limited to the western clients. We have adapted CBT for psychosis in Pakistan for use with local clients. Initial evaluations have found that these therapies are effective. Due to the financial restraints we would like to test a brief version of the Culturally adapted CBTp (CaCBTp) in Pakistan. We want to see if brief CaCBTp (6 sessions of CBT) would be effective in non western cultures in educing symptoms of schizophrenia. This study will test brief CaCBTp against care as usual in Pakistan in secondary care.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

BACKGROUND A number of systematic reviews and meta-analyses (for example, Wykes, Steel, Everitt, & Tarrier, 2008) have concluded that Cognitive Behaviour Therapy (CBT) is effective in treating people with schizophrenia. Most of this work was however, conducted in the West. In a literature search no study of CBT for psychosis in English language literature was found from a low or middle income country, including from Pakistan. Only two studies of psychological interventions for schizophrenia were found from Pakistan (Farooq et al., 2011; Nasr, Kausar, & others, 2009).

It has been suggested that cultural differences can influence the process of Cognitive Behaviour Psychotherapy, and therefore therapy might need adapting to the cultural needs of a given country. Our group has adapted Cognitive Therapy for depression in Pakistan (F. Naeem, Ayub, Gobbi, & Kingdon, 2009; F. Naeem, Gobbi, Ayub, Kingdon, & others, 2010; Farooq Naeem, Ayub, Kingdon, & Gobbi, 2012; Farooq Naeem, Gobbi, Ayub, & Kingdon, 2009) , which was found to be effective in a small trial (Farooq Naeem, Waheed, Gobbi, Ayub, & Kingdon, 2011). Same methodology was useed to adapt CBT for schizophrenia for local use (Naeem et al, under review). A small pilot found it to be effective in inpatient settings. (Habib et al, under review). This is a RCT to test the effectiveness of Culturally adapted CBT for psychosis (CaCBTp).

METHODS Aims The aim of this RCT is to test brief culturally adapted Cognitive Therapy for Schizophrenia against Treatment As Usual in Pakistan.

Study area and population:

Study participants will be recruited mainly from hospitals in Lahore/Karachi, Pakistan.

Sample Inclusion criteria include;

  • living within travelling distance of the hospital
  • and with a diagnosis of Schizophrenia according to ICD10, RDC
  • age between 18 to 65 years
  • and at least 5 years of education/ or the main carer with at least 5 years of education. The exclusion criteria include;
  • co-morbid alcohol or substance dependence
  • organic brain syndrome or learning disability
  • and high levels of disturbed behavior/or high risk of suicide or homicide.

Sample size The sample size was calculated on showing a difference in the post-treatment PANSS positive symptoms score between groups. A previous study (reference in here?) found a standard deviation for the post-treatment scores of 5.8 in the control group, and 1.8 in the CBT group. In the analysis, the pre-treatment scores will be adjusted for, and the previous study found a correlation of 0.2 between the pre and post treatment scores. A difference between groups of 15% of the pre-treatment values would be regarded as being of clinical importance. This equates to a difference of 3 units on the PANNS positive symptoms score scale. Using a 5% significance level and 90% power, it is calculated that 41 subjects per group are required, 82 in total. It is expected that up to 30% of patients may drop-out of the study. To allow for this, a total of 120 patients will be recruited into the study.

Procedure Mental health professional from the hospitals will be contacted and the purpose of the study will be explained to them. Patients referred by them received information about the study. After taking informed consent participants will be assessed by blind assessors who will be psychology graduates and had received one day training in using assessment tools. After completion of the assessment, participants will be randomly assigned to either CBT or Treatment As Usual group. Randomization will be performed using randomization.com.

Ethical approval The Ethics Committee of Pakistan Association of Cognitive Therapists (PACT) has granted ethical approval for this study.

Measures Data regarding demographic characteristics will be collected using a data collection form. Psychopathology will be measured using the PANSS (Positive and Negative Syndrome Scale of Schizophrenia), PSYRATS (Psychotic Symptom Rating Scales), and the Insight Scale. The above scales were translated into Urdu using standard methodology(Ahmer, Faruqui, & Aijaz, 2007). Positive and Negative Syndrome Scale of Schizophrenia (PANSS) (Kay, Flszbein, & Opfer, 1987) is a widely used, well established and comprehensive symptom rating scale measuring mental state. It has 30 items, each measured on a seven point rating instrument. There are three sub-scales (Positive Symptoms, Negative Symptoms and General Psychopathology) along with a total score. The test re test reliability of PANSS is 0.88 and Criterion related validity is 0.62. The Structured Clinical Interview for PANSS (SCI-PANSS) (Kay, 1991) was used in this study.

Psychotic Symptom Rating Scales (PSYRATS) (Gillian Haddock, McCarron, Tarrier, & Faragher, 1999) is a 17 item interviewer scored instrument which consist of 2 subscales (PSYRATS Voice, PSYRAT Delusion) which measures the severity of a number of dimensions of auditory hallucinations and delusions including the amount and intensity of distress associated with these symptoms. The 11 item hallucination sub-scale consists of items such as frequency, duration, loudness, negative content, intensity of distress and degree of disruption. The six item delusion sub-scale (PSYRATS delusion) consists of items such as amount of pre-occupation, degree of conviction, intensity of distress and disruption. All items are rated on a five point scale of increasing severity (0 = No problem to 4 = Maximum severity). The PSYRATS has demonstrated good inter rater reliability (intra class correlation (ICCS) for most item > .90), test re test reliability (ICCS for both subscales = .70), concurrent validity, and sensitivity to change in patients diagnosed with Schizophrenia.

Insight will be rated using the Schedule for Assessment of Insight (SAI) (David, Buchanan, Reed, & Almeida, 1992). The SAI rates three dimensions of insight; Treatment Adherence (SAI-TA), Recognition of Illness (SAI-RI) and Symptom Relabelling (SAI-SR). Symptom Relabelling involves the recognition of a psychotic symptom and the understanding that it is a pathological event. Each dimension comprises two or three questions which are scored on a 3-point scale from 0 (no insight) to 2 (good insight), with a maximum total score of 24. The sub-scale totals are summed for a total insight score.

Brief disability rating questionnaire will be used to measure change in level of disability.

Intervention The CBT intervention will consist of 6 session sessions lasting approximately one hour. There will be one additional session for the family. It has been observed that family members are involved actively in patient care in Pakistan, so the main carer/family member will be involved in the treatment plan from the beginning. A key carer will be identified with whom researcher will work in close collaboration. This person helped with homework if required. The sessions will be planned according to a manualized treatment protocol (Kingdon & Turkington, 1994). Therapy will be delivered using guidelines developed for cultural adaptation in Pakistan and therapists will receive regular supervision on skype. CBT was adapted using a series of qualitative studies (Naeem et al, 2010, 2009, 2010, 2009, accepted for publication, under review). An initial pilot project found this culturally adapted CBT for psychosis to be effective in Pakistan (Habib et al, unde review)

TAU Group The Treatment As Uusual (TAU) group will receive only antipsychotic medication as prescribed by the psychiatrist, regular follow up and nursing care.

STATISTICAL ANALYSES Both parametric and non parametric tests will be carried out. Initially data will be examined for errors in input. The analysis will be carried out on intention to treat basis using SPSS version 16.0. Initial analyses to compare the two groups were carried out using t test and χ2 test. A linear regression analysis will be used, with end of therapy as the dependent variable and group allocation, as independent variable. In order to see the effect of baseline differences in pre treatment scores on effect of therapy a second analysis was carried out with baseline scores entered as independent variables in addition to treatment groups (i.e., dependent variable post treatment scores, independent variable treatment group and pre treatment scores).

Study Type

Interventional

Enrollment (Actual)

120

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Pakistan
      • Lahore, Pakistan
        • Pakistan Association of Cognitive Therapists

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • being able to engage with a therapist,
  • living within travelling distance of the hospital, and
  • with a diagnosis of Schizophrenia according to DSM-IV-TR (Association & DSM-IV, 2000),
  • age between 18 to 65 years.

Exclusion Criteria:

  • co-morbid alcohol or substance dependence,
  • organic brain syndrome or learning disability and high levels of disturbed behavior, or
  • high risk of suicide or homicide.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Brief CaCBTp
The experimental group will receive brief for of Culturally adapted CBT for psychossis
Behavioral: Brief CaCBTp
Brief CBT for psychosis is comonly used in the West and had an established evidence base. Recently this therapy has been culturally adapted for use with clients from Pakistan.
Other Names:
  • RCT of Brief CaCBT for Psychosis
No Intervention: Treatment As Usual
Treatment as usual means seeing a mental health professional and taking the prescribed anti psychotics and being cared by family members

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
PANSS (Positive and Negative Syndrome Scale of Schizophrenia)Positive symptoms
Time Frame: Participants will be assessed at baseline and then end of therapy at 12 weeks
Measurement of positive symptoms
Participants will be assessed at baseline and then end of therapy at 12 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
PANSS (Positive and Negative Syndrome Scale of Schizophrenia)Negative symptoms
Time Frame: Participants will be assessed at baseline and then end of therapy at 12 weeks
Negative symptoms of psychosis
Participants will be assessed at baseline and then end of therapy at 12 weeks
PSYRATS (Psychotic Symptom Rating Scales)
Time Frame: Participants will be assessed at baseline and then end of therapy at 12 weeks
measurement of Delusions and Hallucinations
Participants will be assessed at baseline and then end of therapy at 12 weeks
Schedule for Assessment of Insight
Time Frame: Participants will be assessed at baseline and then end of therapy at 12 weeks
Measurement of Insight into the illness
Participants will be assessed at baseline and then end of therapy at 12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Pakistan Association of Cognitive Therapists

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

February 1, 2013

Primary Completion (Actual)

July 1, 2014

Study Completion (Actual)

July 1, 2014

Study Registration Dates

First Submitted

April 29, 2013

First Submitted That Met QC Criteria

June 11, 2013

First Posted (Estimate)

June 12, 2013

Study Record Updates

Last Update Posted (Estimate)

October 29, 2014

Last Update Submitted That Met QC Criteria

October 27, 2014

Last Verified

October 1, 2014

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • PACT_CAPRCT_120310

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Schizophrenia

Clinical Trials on Brief CaCBTp

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe